Henry Schein, the global distributor of medical and dental supplies, has revised how it calculates its “adjusted” earnings, a move that brings more transparency but also lowers the bar for what investors can expect in 2026. Morgan Stanley, which follows the stock, said the refreshed numbers make operations easier to read—but they also cut the company’s adjusted earnings guidance for next year and point to a softer fourth quarter than previously thought.
What changed in the numbers
Henry Schein now strips out certain “acquisition gains” from its adjusted profit figures. That’s a common practice: companies often exclude one-time or non-operating items to give investors a clearer view of ongoing business performance. But tightening that definition also removes some of the padding that had been boosting the numbers.
As a result, the company trimmed its 2026 adjusted earnings per share (EPS) guidance to a range of $5.42 to $5.48, down from the earlier $5.50 to $5.56. That’s a modest cut on the surface, but it resets the baseline that analysts and investors use to value the stock.
Morgan Stanley also noted that the recast 2025 earnings before interest, taxes, depreciation, and amortization (EBITDA) base implies about an 8% drop in fourth-quarter EBITDA, versus roughly flat growth previously. EBITDA is a measure of profitability that strips out financing and accounting decisions, and it’s a key metric for valuing distributors like Henry Schein.
Why the lower base matters
Investors often value companies like Henry Schein based on forward profit and EBITDA. A lower, less “repeatable” base can make next year’s growth bridge look less certain. In other words, if the starting point is weaker, it’s harder to show strong year-over-year growth—even if the underlying business is doing fine.
Morgan Stanley kept its underweight rating on the stock, even as it lifted its 2026 EPS estimate to $5.42 and raised its price target to $68. The bank cited mixed underlying growth and flagged that prior results were helped by a $0.19 tariff refund that’s unlikely to repeat. Revenue guidance was maintained rather than raised, which adds to the cautious tone.
What it means for investors
When a company “refreshes” its adjusted reporting, investors usually appreciate the added transparency. But they often pay a lower valuation multiple if the new view removes one-time items and pulls down the starting line. That’s exactly the tension here: Morgan Stanley’s $68 target implies about 12.5 times its 2026 EPS estimate of $5.42. The stock recently traded around $84.61, which works out to roughly 15.6 times that same figure.
So even if estimates hold up, the share price may hinge more on what investors decide is a fair multiple for the newly defined, less padded profit stream. The debate shifts from “did they beat?” to “how much should the market pay for these earnings?”
For everyday investors, this is a reminder that accounting changes can have real consequences for stock prices. When a company alters how it reports adjusted earnings, it’s worth digging into what’s being excluded and how that affects the numbers you’re using to judge the business. In this case, the cleaner view also reveals a softer near-term outlook, which is why the stock may face headwinds even if the underlying operations are stable.
Morgan Stanley’s cautious stance fits with a broader theme in the market: investors are increasingly scrutinizing the quality of earnings and the sustainability of growth. As Morgan Stanley's own macro outlook suggests, the economic environment is getting more complex, and companies that rely on one-time boosts may find it harder to impress.
For now, Henry Schein’s story is about a company that’s cleaning up its financial reporting, but that cleanup comes with a lower starting point for 2026. Whether that’s a buying opportunity or a warning sign depends on how much faith investors place in the underlying business—and what multiple they’re willing to pay for it.


